Cristina V. Campos

Valencia, VC, Spain

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 18 publications

Real-world use of ixekizumab for axial spondyloarthritis treatment in Spain (ESPADA study).

Real-world use of ixekizumab for axial spondyloarthritis treatment in Spain (ESPADA study).

Journal: Frontiers in medicine

Published: September 12, 2025

SUBCUTANEOUS VERSUS INTRAVENOUS TOCILIZUMAB IN AORTITIS ASSOCIATED WITH GIANT CELL ARTERITIS: MULTICENTER STUDY OF 196 PATIENTS.

SUBCUTANEOUS VERSUS INTRAVENOUS TOCILIZUMAB IN AORTITIS ASSOCIATED WITH GIANT CELL ARTERITIS: MULTICENTER STUDY OF 196 PATIENTS.

Journal: Arthritis care & research

Published: August 26, 2025

Subcutaneous Versus Intravenous Tocilizumab in Aortitis Associated With Giant Cell Arteritis: Multicenter Study of 196 Patients.

Subcutaneous Versus Intravenous Tocilizumab in Aortitis Associated With Giant Cell Arteritis: Multicenter Study of 196 Patients.

Journal: Arthritis care & research

Published: August 26, 2025

Cancer risk in patients with rheumatoid arthritis receiving biologic and targeted synthetic disease-modifying antirheumatic drugs: results from the BIOBADASER III registry.

Cancer risk in patients with rheumatoid arthritis receiving biologic and targeted synthetic disease-modifying antirheumatic drugs: results from the BIOBADASER III registry.

Journal: Rheumatology (Oxford, England)

Published: July 22, 2025

Effectiveness Of Tocilizumab In Aortitis And Aneurysms Associated With Giant Cell Arteritis.

Effectiveness Of Tocilizumab In Aortitis And Aneurysms Associated With Giant Cell Arteritis.

Journal: European journal of internal medicine

Published: December 06, 2023

Impact of multimorbidity on the first ts/bDMARD effectiveness and retention rate after two years of follow-up in patients with rheumatoid arthritis from the BIOBADASER registry.

Impact of multimorbidity on the first ts/bDMARD effectiveness and retention rate after two years of follow-up in patients with rheumatoid arthritis from the BIOBADASER registry.

Journal: Arthritis research & therapy

Published: October 29, 2023

Correction: Factors associated with discontinuation of biologics in patients with inflammatory arthritis in remission: data from the BIOBADASER registry.

Correction: Factors associated with discontinuation of biologics in patients with inflammatory arthritis in remission: data from the BIOBADASER registry.

Journal: Arthritis research & therapy

Published: October 26, 2023

Real-world persistence of initial targeted therapy strategy in monotherapy versus combination therapy in patients with chronic inflammatory arthritis.

Real-world persistence of initial targeted therapy strategy in monotherapy versus combination therapy in patients with chronic inflammatory arthritis.

Journal: European journal of clinical investigation

Published: May 09, 2023

Effects of COVID-19 vaccination on disease activity in patients with rheumatoid arthritis and psoriatic arthritis on targeted therapy in the COVIDSER study.

Effects of COVID-19 vaccination on disease activity in patients with rheumatoid arthritis and psoriatic arthritis on targeted therapy in the COVIDSER study.

Journal: RMD open

Published: December 15, 2022

Factors associated with discontinuation of biologics in patients with inflammatory arthritis in remission: data from the BIOBADASER registry.

Factors associated with discontinuation of biologics in patients with inflammatory arthritis in remission: data from the BIOBADASER registry.

Journal: Arthritis research & therapy

Published: November 10, 2022

Correction to: Real-World Effectiveness and Treatment Retention of Secukinumab in Patients with Psoriatic Arthritis and Axial Spondyloarthritis: A Descriptive Observational Analysis of the Spanish BIOBADASER Registry.

Correction to: Real-World Effectiveness and Treatment Retention of Secukinumab in Patients with Psoriatic Arthritis and Axial Spondyloarthritis: A Descriptive Observational Analysis of the Spanish BIOBADASER Registry.

Journal: Rheumatology and therapy

Published: September 05, 2022

Female Sex, Age, and Unfavorable Response to Tumor Necrosis Factor Inhibitors in Patients With Axial Spondyloarthritis: Results of Statistical and Artificial Intelligence-Based Data Analyses of a National Multicenter Prospective Registry.

Female Sex, Age, and Unfavorable Response to Tumor Necrosis Factor Inhibitors in Patients With Axial Spondyloarthritis: Results of Statistical and Artificial Intelligence-Based Data Analyses of a National Multicenter Prospective Registry.

Journal: Arthritis care & research

Published: April 06, 2022

Showing 1-12 of 18

Last Updated: 09/26/2026